Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305799 · ClinicalTrials.gov registry record
Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors
A clinical trial, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- 59
- Enrollment target
NCT00305799 is a clinical trial that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 59 participants.
The verdict
NCT00305799 has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 59 participants
- Enrollment target
Study Summary
RATIONALE: Understanding how oxaliplatin affects hearing loss, dizziness, and peripheral neuropathy may improve the ability to plan effective treatment for patients receiving oxaliplatin for solid tumors. PURPOSE: This clinical trial is studying hearing loss and dizziness in patients receiving oxaliplatin for solid tumors.
Interventions
- PROCEDURE management of therapy complications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2005-11 |
| Est. Completion | 2014-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00305799
The ClinicalTrials.gov registry entry for NCT00305799 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which management of therapy complications is the first listed.
NCT00305799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00305799 about?
NCT00305799 is a clinical study titled "Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors". RATIONALE: Understanding how oxaliplatin affects hearing loss, dizziness, and peripheral neuropathy may improve the ability to plan effective treatment for patients receiving oxaliplatin for solid tumors. PURPOSE: This clinical trial is studying hearing loss and dizziness in patients receiving oxal...
What is the current status of trial NCT00305799?
This trial is currently completed. The enrollment target is 59 participants. The study started on 2005-11. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00305799?
The interventions under investigation include: management of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT00305799?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.